|
[1]
|
Zhao, F.J., Su, Q., Zhang, W., et al. (2021) Endu Combined with Concurrent Chemotherapy and Radiotherapy for Stage IIB-IVA Cervical Squamous Cell Carcinoma Patients. World Journal of Clinical Cases, 9, 8061-8070. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Torre, L.A., Bray, F., Siegel, R.L., et al. (2015) Global Cancer Sta-tistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87-108. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Datta, N.R., Stutz, E., Liu, M., et al. (2017) Concurrent Chemoradiotherapy vs. Radiotherapy Alone in Locally Advanced Cervix Cancer: A Systematic Review and Meta-Analysis. Gynecologic Oncology, 145, 374-385. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Jain, R.K. (2005) Normalization of Tumor Vasculature: An Emerg-ing Concept in Antiangiogenic Therapy. Science, 307, 58-62. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Lee, W.S., Yang, H., Chon, H.J., et al. (2020) Combination of Anti-Angiogenic Therapy and Immune Checkpoint Blockade Normalizes Vascular-Immune Crosstalk to Potentiate Cancer Immunity. Experimental & Molecular Medicine, 52, 1475-1485. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Koo, H.J., Lee, M., Kim, J., et al. (2016) Synergistic Effect of Anti-Angiogenic and Radiation Therapy: Quantitative Evaluation with Dynamic Contrast Enhanced MR Imag-ing. PLOS ONE, 11, e148784. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Apte, R.S., Chen, D.S. and Ferrara, N. (2019) VEGF in Sig-naling and Disease: Beyond Discovery and Development. Cell, 176, 1248-1264. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
罗红, 张瑞新, 宁方玲. 抗肿瘤血管靶向药物的作用及应用研究[J]. 医学信息, 2021, 34(6): 40-42.
|
|
[10]
|
Pinheiro, C., Garcia, E.A., Morais-Santos, F., et al. (2015) Reprogramming Energy Metabolism and Inducing Angiogenesis: Co-Expression of Monocarboxylate Transporters with VEGF Family Members in Cervical Adenocarcinomas. BMC Cancer, 15, Article No. 835. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Falcon, B.L., Chintharlapalli, S., Uhlik, M.T., et al. (2016) An-tagonist Antibodies to Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) as Anti-Angiogenic Agents. Phar-macology & Therapeutics, 164, 204-225. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Jiang, X., Wang, J., Deng, X., et al. (2020) The Role of Mi-croenvironment in Tumor Angiogenesis. Journal of Experimental & Clinical Cancer Research, 39, Article No. 204. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Liu, F.W., Cripe, J. and Tewari, K.S. (2015) Anti-Angiogenesis Therapy in Gynecologic Malignancies. Oncology (Williston Park), 29, 350-360.
|
|
[14]
|
Seol, H.J., Ulak, R., Ki, K.D., et al. (2014) Cytotoxic and Targeted Systemic Therapy in Advanced and Recurrent Cervical Cancer: Experience from Clinical Trials. The Tohoku Journal of Experimental Medicine, 232, 269-276. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
王俊杰, 徐辉, 齐华, 等. 贝伐珠单抗在宫颈癌肺转移中的疗效及安全性评价[J]. 中华转移性肿瘤杂志, 2022, 5(2): 142-146.
|
|
[16]
|
Schefter, T.E., Winter, K., Kwon, J.S., et al. (2012) A Phase II Study of Bevacizumab in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma: Preliminary Results of RTOG 0417. International Journal of Radi-ation Oncology, Biology, Physics, 83, 1179-1184. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Schefter, T., Winter, K., Kwon, J.S., et al. (2014) RTOG 0417: Efficacy of Bevacizumab in Combination with Definitive Radiation Therapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma. International Journal of Radiation Oncology, Biology, Physics, 88, 101-105. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Waliany, S., Sainani, K.L., Park, L.S., et al. (2019) Increase in Blood Pressure Associated with Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor. JACC: Car-dioOncology, 1, 24-36. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Sandler, A., Gray, R., Perry, M.C., et al. (2006) Paclitax-el-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 355, 2542-2550. [Google Scholar] [CrossRef]
|
|
[20]
|
Gyawali, B. and Iddawela, M. (2017) Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries. JCO Global Oncology, 3, 93-97. [Google Scholar] [CrossRef]
|
|
[21]
|
Wang, Y., Deng, M., Chen, Q., et al. (2019) Apatinib Ex-erts Anti-Tumor Activity to Non-Hodgkin Lymphoma by Inhibition of the Ras Pathway. European Journal of Pharma-cology, 843, 145-153. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Serova, M., Tijeras-Raballand, A., Dos, S.C., et al. (2016) Everolimus Affects Vasculogenic Mimicry in Renal Carcinoma Resistant to Sunitinib. Oncotarget, 7, 38467-38486. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
张海利, 董桂兰, 刘丽丽, 等. 阿帕替尼治疗多线化疗后复发的广泛期小细胞肺癌的效果及对患者生存的影响[J]. 中国医药导报, 2019, 16(26): 100-103.
|
|
[24]
|
潘国友, 郭慧, 王聪, 等. 阿帕替尼对二线化疗耐药复发宫颈鳞状细胞癌的疗效观察[J]. 中国肿瘤临床, 2019, 46(15): 813.
|
|
[25]
|
Li, F., Liao, Z., Zhao, J., et al. (2017) Efficacy and Safety of Apatinib in Stage IV Sarcomas: Experience of a Major Sarcoma Center in China. Oncotarget, 8, 64471-64480. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Xu, J., Liu, X., Yang, S., et al. (2018) Clinical Response to Apatinib Monotherapy in Advanced Non-Small Cell Lung Cancer. Asia-Pacific Journal of Clinical Oncology, 14, 264-269. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Liang, L., Wang, L., Zhu, P., et al. (2018) A Pilot Study of Apatinib as Third-Line Treatment in Patients with Heavily Treated Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 17, e443-e449. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Kong, Y., Sun, L., Hou, Z., et al. (2017) Apatinib Is Effective for Treatment of Advanced Hepatocellular Carcinoma. Oncotarget, 8, 105596-105605. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Zhu, B., Li, J., Xie, Q., et al. (2018) Efficacy and Safety of Apatin-ib Monotherapy in Advanced Bone and Soft Tissue Sarcoma: An Observational Study. Cancer Biology & Therapy, 19, 198-204. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Li, L., Xiao, S., Zhang, L., et al. (2018) An Open Label, Single-Armed, Exploratory Study of Apatinib (a Novel VEGFR-2 Tyrosine Kinase Inhibitor) in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Oncotarget, 9, 16213-16219. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Miao, M., Deng, G., Luo, S., et al. (2018) A Phase II Study of Ap-atinib in Patients with Recurrent Epithelial Ovarian Cancer. Gynecologic Oncology, 148, 286-290. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
刘秋利, 李婧, 李娟, 等. 阿帕替尼对宫颈癌细胞增殖及化疗敏感性的影响[J]. 现代妇产科进展, 2017, 26(11): 806-809.
|
|
[33]
|
刘伟, 张建文. 阿帕替尼对宫颈癌HeLa细胞体外放射作用的研究[J]. 中国药业, 2017, 26(19): 27-30.
|
|
[34]
|
Xiao, Y., Cheng, H., Wang, L., et al. (2020) Clinical Response and Safety of Apatinib Monotherapy in Recurrent, Metastatic Cervical Cancer after Failure of Chemotherapy: A Retrospective Study. Gynecologic Oncology, 31, e2. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Li, N., Wang, Z., Yuan, G., et al. (2020) An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study. Journal of Oncology, 2020, Article ID: 3852373. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Yu, J., Xu, Z., Li, A., et al. (2019) The Efficacy And Safety of Apatinib Treatment for Patients with Metastatic or Recurrent Cervical Cancer: A Retrospective Study. Drug Design, Development and Therapy, 13, 3419-3424. [Google Scholar] [CrossRef]
|
|
[37]
|
Chen, C., Qin, S., Li, Z., et al. (2019) A Retrospective Six-Patient Series of Apatinib for the Treatment of Persistent or Recurrent Carcinoma of the Cervix. OncoTargets and Therapy, 12, 5805-5811. [Google Scholar] [CrossRef]
|
|
[38]
|
Xia, X., Jiang, W., Qi, W., et al. (2020) Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radio-therapy and First-Line Chemotherapy: A Prospective Study. Oncology Research and Treatment, 43, 649-655. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Funakoshi, T., Latif, A. and Galsky, M.D. (2013) Risk of Hematologic Toxicities in Cancer Patients Treated with Sunitinib: A Systematic Review and Meta-Analysis. Cancer Treatment Re-views, 39, 818-830. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Mackay, H.J., Tinker, A., Winquist, E., et al. (2010) A Phase II Study of Sunitinib in Patients with Locally Advanced or Metastatic Cervical Carcinoma: NCIC CTG Trial IND.184. Gy-necologic Oncology, 116, 163-167. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Song, H.F., Liu, X.W., Zhang, H.N., et al. (2005) Pharmacoki-netics of His-tag Recombinant Human Endostatin in Rhesus Monkeys. Acta Pharmacologica Sinica, 26, 124-128. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
柯庆华, 周世琼, 胡艳, 等. 重组人血管内皮抑制素(恩度)联合放疗同步治疗中晚期宫颈癌48例的近期疗效[J]. 现代肿瘤医学, 2011, 19(10): 2066-2068.
|
|
[43]
|
Guo, F., Chen, C., Liang, Y., et al. (2020) Efficacy of the Combination of Endostar with Chemotherapy on Stage IVb and Recur-rent Metastatic Cervical Cancer. Journal of Central South University. Medical Sciences, 45, 1412-1418.
|
|
[44]
|
邹怡华, 王侠, 毕春, 等. 恩度联合同步放化治疗宫颈癌疗效的Meta分析[J]. 医学研究杂志, 2023, 52(1): 158-163.
|